cfDNA and Sequencing, a “one-two punch” to knock out cancer at Round 1
Jul 20, 2023
Share article
Dr. Weilin Liu - Field Application Scientist at MGI
The Role of cfDNA in Early Cancer Detection
Cancer has been shown by sufficient clinical studies to have a better prognosis and survival rate when diagnosed and treated earlier, thus early detection of cancers and their markers serves as a pivotal role in cancer intervention and treatment. Cell-free DNA (cfDNA) provides a non-invasive and easily accessible way for multi-cancer early detection and monitoring due to the presence of circulating tumor DNA (ctDNA), which reflects tumor-specific genetic and epigenetic alternations, and are physically shorter than normal cfDNAs. However, such an early detection by cfDNA-based liquid biopsy method still remains as a challenge due to its yet to be improved sensitivity when comparing with late-stage detection.
Enhancing Cancer Prognosis with Integrative Modeling
To tackle this issue and further enhanced cancer prognosis, a cornerstone work on integrative modeling Bae et al., Nat Commun, 2023 of tumor genomes and epigenomes cfDNA has been recently published in Nature Communication, showing its algorithm detects early-stage cancers with high sensitivity that is comparable to that of late-stage detection. Moreover, the model interpretation reveals the contribution of cancer type-specific genomic and epigenomic features. A total of 3366 samples were split into 2 cohorts sequenced on MGI DNBSEQ G400 and Illumina Novaseq-6000 using PE100, respectively.
Superior Performance of MGI Data and Future Directions
At 95% specificity, the combined model had a higher sensitivity of 91.1% on the MGI data for stage I cancers than that of 79.6% from Illumina data. Moreover, per tumor type evaluation was performed to reveal the accuracy of localizing the tissue of origin. The genome and epigenome models by both the MGI and Illumina cohorts outperformed the existing methods, and further improvements were achieved when combing the two models. Overall speaking, a better performance is achieved on the MGI data compared with the Illumina data implies that superior data quality and higher read depths achieved by MGI DNBSEQ platform together its cfDNA library kit contribute to prediction accuracy. The methodologies proposed in this study lay the foundation for accurate cfDNA-based cancer diagnosis, especially at early stages. The results could be further improved when coupling with integrative modeling based on tumor biology, an increasing amount of reference and cfDNA analysis training data to accomplish ultrasensitive early cancer detection and accurate cancer diagnosis.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
mRNA Vaccine Development
Next-Generation Sequencing
VAX-seq Workflow
Nobel Prize in Medicine
Share this article :
Share
More Science
Mar 5, 2024
Smart-seq3Xpress: a scalable, high-sensitivity and low-cost Single cell Full-length RNA-seq methodology.
Revolutionizing single-cell RNA-seq, SMART-seq3Xpress offers unparalleled sensitivity and cost-efficiency with full-length coverage.
Jan 10, 2024
Single-cell Spatial transcriptomics (sc-StereoSeq), opening a new era in plants and crops biology.
Explore how sc-StereoSeq is transforming our understanding of plant biology, from crop production to plant stress responses, marking a new era in spatial transcriptomics.
Oct 10, 2023
Can Next-generation Sequencing accelerate mRNA vaccine development?
Explore the transformative impact of Next-Generation Sequencing in mRNA vaccine development. Dive into Nobel-winning discoveries, challenges, and novel technologies like the VAX-seq workflow, enhancing vaccine production, safety, and quality analysis amidst global health crises.